Medical Malpractice Insurance News

In the increasingly competitive profession of dentistry, dentists search for an edge to set them apart. Botox is marketed as a way to increase patient traffic to the dental office. However, the use of Botox in dentistry carries additional risks that dentists should know about.

Given the vast array of dietary supplements on the market—some of which may be ineffective or potentially harmful—it’s more important than ever to discuss these products with patients.

Experts say patient-centric opioid intervention before discharge from the hospital can cut overall opioid intake, while still ensuring a patient is satisfied and their pain is properly managed.

The U.S. Food and Drug Administration issued an emergency use authorization for simultaneous administration of monoclonal antibodies bamlanivimab and etesevimab to treat COVID-19 patients who meet specific criteria.

The U.S. Food and Drug Administration is evaluating the potential impact of SARS-CoV-2 viral mutations on authorized molecular tests.

The U.S. Food and Drug Administration released an AI/ML-Based Software as a Medical Device Action Plan, which outlines a detailed approach to ensuring the safety and efficacy of these technologies.

The U.S. Food and Drug Administration cautions that patients can be injured if wearing face masks with metal features or coating during an MRI exam.

The U.S. Food and Drug Administration has granted Eli Lilly and Company an emergency use authorization for bamlanivimab to treat mild-to-moderate COVID-19 in adult and pediatric patients.

The U.S. Food and Drug Administration has approved the antiviral drug remdesivir, sold as Veklury, to treat COVID-19 patients who meet specific criteria.

Dental amalgam is “durable, safe and effective” despite containing mercury, the American Dental Association reaffirmed, responding to a recent statement by the Food and Drug Administration.